ABSTRACT -tert-Butylhydrazine monohydrochloride was daily administered by gavage to groups of Crl:CD (SD)IGS rats at doses of 0 (control), 0.8, 4, or 20 mg/kg/day. Twelve males per group were treated for a total of 42 days from 14 days before mating. Twelve females per group were treated from 14 days before mating to day 4 of lactation throughout the mating and gestation periods. Recovery groups of five males and five non-pregnant females per group were dosed for 42 days followed by a 14-day recovery period. No deaths were observed in any groups of either sex. There were no considerable changes in body weight, food intake, general appearance, functional observations or biochemical analysis. Values of the anemic parameters were decreased in the 20 mg/kg/day males and in all female dose groups. The relative weight of the liver, kidneys and spleen was significantly increased in 20 mg/kg/day females. Histopathological examination showed congestion and hemosiderin deposition in the spleen at 20 mg/kg/day in both sexes, but there were no changes in the liver or kidneys in either sex. Anemic parameters with hemosiderin deposition did not completely recover in the 20 mg/kg/day group in both sexes after the recovery period. As for reproduction, a significant reduction was only observed in the number of corpora lutea at 20 mg/kg/day. It was thus concluded that the LOAEL was 0.8 mg/kg/day based on the decreased values of the anemic parameters of repeated-dose toxicity, and that the NOAEL was 4 mg/kg/day based on the low number of corpora lutea of reproductive/developmental toxicity. 
INTRODUCTION
tert-Butylhydrazine monohydrochloride (tBH; CAS No. 7400-27-3) is a white crystalline powder with a melting point of >190°C and solubility of 740 g/l H 2 O at 25°C. It is used as an intermediate in the production of pesticides, medicines, and resin blowing agents. The volume produced in Japan was reported as 200 tons/year in 2005. The oral LD 50 has been shown to be 592-769 mg/kg in male rats and 680 mg/kg in female rats (Chemical Daily, 2007) . However, there is no other toxicological information on tBH. Therefore, the Japanese Ministry of Economy, Trade and Industry requested to conduct a combined repeated-dose and reproductive/developmental toxicity screening test using rats according to the OECD test guideline No. 422 (OECD, 1996) . This test guideline was created for the safety assessment of high production volume chemicals handled by OECD, and has been used for many industrial chemicals, especially those for which Japanese companies are responsible such as 2,2'-azobis(2-methylpropionitrile), diacetone alcohol and pentaerythritol (IPCS INCHEM) . This test guideline provides a very useful and effective testing method because although it is a single test, it gives both data for repeated-dose toxicity and reproductive/developmental toxicity, which are the minimum requirements for the Screening Information Data Sets of the OECD chemical assessment.
Recently the safety assessments of several chemicals performed using this test guideline have been reported in toxicological journals (Tanaka et al., 1992; Malley et al., 2002; Sato et al., 2005; Matsumoto et al., 2008; Chung et al., 2009; Hirata-Koizumi et al., 2012) .
A number of toxicity information on hydrazine which is the fundamental structure of tBH, has been summarized and assessed (EHC, 1987; US ATSDR, 1997; NEDO, 2005) . Focusing on rat studies the systemic toxicity of hydrazine is unclear although it is relatively toxic since the oral LD 50 is 60 mg/kg and it has irritant and corrosive properties. Repeated oral administration of hydrazine to rats induced body weight loss and death, but did not indicate any specific toxicity (Steinhoff and Mohr, 1988) . The inhaled exposure to rats showed hepatocyte hypertrophy and degeneration of the cardiac muscle in addition to damage of the respiratory tract due to its irritant property (Vernot et al., 1985) . Recently, it was reported that hydrazine induced hemolytic anemia as the most sensitive adverse effect in a repeated-dose 28-day oral toxicity test in rats (MHLW, 2003a) . This is the first actual report on the in vivo effect on red blood cells in rats although hydrazines generally represent a class of agents that is known to have potent hemolytic activity on red blood cells (Runge-Morris et al., 1994) . As for reproductive/developmental toxicity of hydrazine in rats, pregnancy could not be maintained and the index of pups' viability was decreased in a preliminary reproduction test (MHLW, 2003b) .
There are several reports that demonstrate the effect of other hydrazine derivatives on the health of rats. 1,1-Dimethyhydrazine (CAS No. 57-14-7) inhaled for 7 weeks at only a single-dose level (75 ppm, 6 hr/day, 5 days/week) induced death or nervous and respiratory symptoms, but no histopathological changes in any organs (Rinehart et al., 1960) . This chemical injected intraperitoneally for 3 weeks at up to 70 mg/kg/day to rats produced only fatty infiltration in the renal tubular epithelium (Cornish and Hartung, 1969) . A single intraperitoneal injection of phenylhydrazine induced striking anemia in rats (Yeshoda, 1942; Berger et al., 1985) but there are no repeated-dose oral toxicity data by the standard test method (CICAD, 2000) . It was reported that acetylphenylhydrazine given orally for 49 to 51 days at 5 mg/kg/day induced strong anemia (Tamuri et al., 1991) . However, this report has only been presented at the annual meeting and has not been published yet. Another hydrazine derivative, 4,4'-ox ybis(benzenesulfonylhydrazide) (CAS No. 80-51-3) was reported to induce weak hemolytic anemia in the standard repeated-dose toxicity test (MHLW, 2004a) . As for the reproductive/developmental toxicity of this chemical, no abnormalities were observed with the standard test method (MHLW, 2004b) .
Based on this information, it is expected that there is a high possibility that tBH may induce hemolytic anemia in rats, because tBH is structurally an intermediate size chemical between hydrazine and phenylhydrazine. There is some possibility that it may demonstrate reproductive/ developmental toxicity because hydrazine was clearly shown to have reproductive toxicity. This article reports the result of both toxicity endpoints in rats according to the officially published test method (OECD test guideline 422) in compliance with Good Laboratory Practice.
MATERIALS AND METHODS
This test was conducted in accordance with OECD guideline 422, "Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test" (OECD, 1996) at the Chemicals Evaluation and Research Institute, Hita (CERI, Oita, Japan). All procedures were performed in accordance with the OECD Principles for Good Laboratory Practice (GLP, November 26, 1997). All animals were treated in compliance with the declaration of Helsinki (Seoul, revised in 2008) and the guideline for animal studies of CERI, Hita, including the animal care principles according to the LABORATORY ANIMAL SCIENCE (1987) of the American Association for Laboratory Animal Science.
from Wako Pure Chemical Industries (Osaka, Japan; Lot. No. DPK0592). The tBH was 99.8% pure and was stored at room temperature (18.3ºC-21.8ºC) in an air-/light-tight container. The tBH was dissolved in purified water, and dosed orally to the animals once daily. Each application volume (4 ml/kg) was calculated based on the latest body weight.
The stabilities of the tBH in 0.500 and 0.0200 w/v% dosing formulation in a light protective cold place for 14 days after dissolving were confirmed using high performance liquid chromatography/mass spectrometry (LC/MS). The concentration of the dosing formulation was analyzed at the time of the first and last preparation using LC/MS, and was confirmed to be within 98.8-102% of the nominal concentration.
Test design
Twelve males and 12 females were administered tBH by gavage at 0, 0.8, 4 and 20 mg/kg/day. The dose-finding test was a 14-day repeated-dose oral toxicity test of tBH that was conducted at 0, 25, 250, 500 and 1,000 mg/kg/day. All males and females in the 250 mg/kg and higher groups died, and symptoms of hemolytic anemia, such as decreased red blood cell count and hematocrit on hematological examination and blackish changes in the spleen on necropsy were observed at 25 mg/kg group in both sexes. Therefore, the doses were set at 0.8, 4 and 20 mg/kg in the main test.
Twelve males in each group were dosed once daily for a total of 42 days beginning 14 days before mating. On the day after the final dosing, seven of the 12 rats in the 0 and 20 mg/kg groups and all rats in the 0.8 and 4 mg/kg groups were sacrificed under ether anesthesia and examined. After the administration period, five males in the 0 and 20 mg/kg groups were reared for 14 days without treatment as recovery groups. Among females, 12 rats in each group were dosed for a total of 42-54 days beginning 14 days before mating to day 4 of lactation throughout the mating and gestation periods. On the day after the final administration, all females were sacrificed and examined. Five females each in the 0 and 20 mg/kg groups were administered without mating for 42 days and reared for the following 14 days as recovery groups. The test outline was shown in Fig. 1 .
Observations and examinations repeated toxicity
General appearance was observed in all animals twice a day during the administration period and once a day during the recovery period. In addition, detailed clinical observations, such as ease of removal from the cage, handling observations and behavior in the arena, were performed once a week in the males, and once a week in weeks 1-5 and on the day before necropsy (day 4 of lactation) in the females. In the males, functional observations, such as the optic, pinna, pain, papillary and air righting reflexes examinations, grip strength (with a automated grip strength meter MATYS, Toyo Sangyo, Toyama, Japan) and locomotor activity count (with a rat activity monitoring system, ACTIMO-10, SHINTECHNO, Fukuoka, Japan), were conducted in five rats in each group in week 6. Five female rats that delivered on the same or almost the same day were examined in each group on the day before necropsy (day 4 of lactation). In the female recovery groups, locomotor activity was measured in recovery week 6. Body weight was measured on days 1, 3, 7, 14, 21, 28, 35, 42 and 43 in males and on days 1, 3, 7 and 14 in the pre-mating period, days 0, 7, 14, 17 and 20 in the gestation period and on days 0, 4 and 5 of lactation in females. The female rats in the recovery groups were weighed on the same days as the males and both sexes were also weighed on days 1, 3, 7, 14 and 15 in the recovery period.
Food intake was measured on days 1, 3, 7, 14, 21, 28, 35 and 42 in males and days 1, 3, 7 and 14 in the pre-mating period, days 0, 7, 14, 17 and 20 in the gestation period, and days 0 and 4 of lactation in females. It was also measured on days 1, 3, 7 and 14 in the recovery period in the recovery groups.
At the termination of administration and in the recovery period, blood samples were collected in five animals per group after overnight fasting from the abdominal aorta under ether anesthesia. A part of the sample was treated with ethylenediaminetetraacetic acid dipotassium (EDTA-2K) and underwent hematological analysis such as red blood cell count, hemoglobin concentration hematocrit value, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), white blood cell count (WBC) and platelet count using CELL-DYN3500 (Abbotto laboratories, Abbotto Park, IL, USA). Reticulocyte count and differential white blood cells were analyzed with ADVIA120 (Siemens, Munich, Germany). Prothrombin time (PT) and activated partial thromboplastin time (APTT) were measured using plasma separated from another part of the sample that was treated with 3.2% sodium citrate with STA Compact (Roche Diagnostics, Basel, Schweiz). Serum or plasma prepared from the other blood samples were analyzed for aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), γ-glutamyltranspeptidase (γ-GTP), total cholesterol (T-Cho), triglyceride (TG), glucose, total protein (T-Protein), albumin, A/G ratio, blood urea nitrogen (BUN), creatinine, total bilirubin (T-Bil), calcium (Ca) and inorganic phosphorus (IP) by 7180 Clinical analyzer (Hitachi High-Tech, Tokyo, Japan). Sodium (Na), potassium (K) and chloride (Cl) were measured with automatic electrolyte analyzer PVA-EX II (A&T, Kanagawa, Japan).
All animals were sacrificed by bleeding from the abdominal aorta under ether anesthesia on the day after the final dosing (main group) or after completion of the recovery period (recovery group), and then the external surface, all orifices, the subcutis, and the cranial, thoracic, abdominal and pelvic cavities and their components were examined macroscopically. The brain, thymus, heart, liver, spleen, kidneys, adrenals, testes, and epididymides were removed and weighed. The pituitary gland, trachea, lungs, axillary lymph nodes, spinal cord, stomach, intestines, mesenteric lymph nodes, urinary bladder, prostate, seminal vesicles, ovaries, uterus, vagina, sciatic nerve and bone marrow (femur) were collected. The testes and epididymides were fixed in modified Davidson's fixative and the other organs and tissues in 10% neutralized formaldehyde solution. In the 0 and 20 mg/kg groups, all organs and tissues were sectioned, stained with hematoxylin-eosin and examined histopathologically under a light microscope. In the lower dose groups the organs in which treatment-related changes had been observed in the higher dose groups were examined. Since hemosiderin deposition was suspected in the spleen, an additional specimen of the spleen that was stained with Berlin blue was prepared and examined.
Reproductive/developmental toxicity data
For each female, the estrous cycle was examined by a vaginal smear from the first day of administration to the day successful mating was verified.
In the main group, each female was moved and cohabited in a cage with a male of the same dose group at night until successful copulation occurred or 2 weeks later. The presence of sperm in the vaginal smear and/or a vaginal plug was considered evidence of mating, and the day of successful mating was designated day 0 of gestation. The pregnant females were allowed to deliver spontaneously and nurse their pups. If the dams built a nest by 15:00, that day was determined as day 0 of lactation or postnatal day 0. In addition, the number of corpora lutea in the ovaries and implantation sites in the uterus were counted at necropsy. The pairing days until copulation, and the copulation, fertilization, conception and implantation indexes, pre/post-implantation loss, and delivered dams and delivery indexes were calculated in each dose group.
The number of pups that were born, stillborns, live pups at birth and live pups at the end of observation, sex ratio of pups born and live pups, and external abnormalities of the live pups were examined on postnatal day 0. In addition, the general appearance and number of live pups were noted once daily up to postnatal day 4. In each pup, the body weight was measured on postnatal days 0 and 4.
Statistical analysis
Body weight, food intake, grip strength, locomotor activity count, hematological and blood chemical parameters, organ weights, estrous cycle length, pairing days until copulation, gestation length, number of corpora lutea, implantation sites, pups born, stillborns, live pups at birth and live pups at the end of observation, sex ratios of pups born and live pups on postnatal days 0 and 4, number of pups at birth with external abnormalities and live pups on postnatal day 4, sex ratio of live pups on postnatal day 4 and the pups' weight on postnatal days 0 and 4 were analyzed by Bartlett's test for homogeneity of variance. If a significant difference (p ≤ 0.05) was not found, one-way analysis of variance was performed. If there was a significant difference (p ≤ 0.05), the values of the 0 mg/kg group and each dose group were analyzed by Dunnett's test. If a significant difference (p ≤ 0.05) was found in Bartlett's test, the Kruskal-Wallis test was used. If there was a significant difference (p ≤ 0.05), the values were analyzed by the nonparametric Dunnett's test.
The numbers of feces and urine pools were analyzed by the Kruskal-Wallis test. Since the results did not show a significant difference, further analysis was not carried out.
Abnormal estrous cyclicity ratio, copulation, fertilization, conception and delivery dam indexes, and sex ratios of live pups at birth and on postnatal days 0 and 4 were analyzed by Fisher's exact test.
The implantation index, pre/post-implantation loss, delivery dam index, external abnormality pups ratio, delivery index and viability indexes on postnatal days 0 and 4 were examined by the Kruskal-Wallis test.
RESULTS

General appearance and functional observations
No clinical findings were noted in either sex during the administration and recovery periods based on daily clinical observations or detailed observations conducted once a week. In the functional observations, high locomotor activity was transiently counted for 50-60 mins in females in the 20 mg/kg group on day 4 of lactation, but it was considered to be incidental because the locomotor activity in the same group was not significantly different from the control for the entire counting period (0-60 mins). No treatment-related changes were noted in the other groups during any periods throughout the test.
Body weight and food intake
No significant changes in body weight in the males were observed during the administration and recovery periods, as shown in Fig. 2 . In females, no significant changes were also noted in each group throughout the before-copulation, gestation and lactation periods (Fig. 3) . In the satellite groups of females, there were also no significant changes in the body weight in the control and high-dose groups, including the recovery period (data not shown).
No significant changes in food intake were noted in males in any periods throughout the test. In females, significant increase was observed on recovery day 14 (data not shown) although it was considered to be incidental since no other related changes were observed.
Hematological examination
Hematological analysis data show that tBH clearly induces anemia in both sexes (Table 1 ). In males, the red blood cell count, hemoglobin concentration, and hematocrit value were significantly decreased by 10% with a 5% increase in MCV at a dose of 20 mg/kg. The significant changes in the red blood cell count and MCV remained at the end of the recovery period. The reticulocyte ratio increased up to 1.8-fold at the end of the recovery period in the 20 mg/kg group, although it did not change at the end of the administration period. In females, the red blood cell count, hemoglobin concentration and hematocrit value decreased in all dosing groups, and the decreases in hemoglobin concentration and hematocrit value were statistically significant even at the low dose of 0.8 mg/kg. The decrease in these three parameters compared to the control was approximately 7% in the 0.8 mg/kg group and 15-20% in the 20 mg/kg group, respectively. MCV was increased only in the 20 mg/kg group, also in the males. The decrease in red blood cell count and the increase in MCV still remained at the end of the recovery period. The reticulocyte ratios were at relatively high levels in the control and all the dosing groups in the administration period, but in the 20 mg/kg group it increased up to 1.6-fold that in the control group at the end of the recovery period.
Blood chemical examination
Blood chemical data are shown in Table 2 . Among the 18 parameters examined at the end of the administration and recovery periods, only four were significantly different from the control in males or females. However, these were not considered to be adverse effects of tBH because all of these changes were only slight or not dose-related.
Organ weights
Significant changes in the absolute or relative organ weights were noted in the heart, thymus, liver, spleen, kidneys or adrenals in the 20 mg/kg group of the main or recovery groups (Tables 3 and 4 ). The decrease in the absolute and relative thymus weights was significant in both sexes, a decrease of approximately 30% in the relative weight. Significance was not noted at the end of the recovery period. Only in females in the 20 mg/kg group the relative organ weights were significantly higher for the liver and kidneys (8-10%) and spleen (26%) at the end of the administration period. The significantly high relative liver weight still remained at the end of the recovery period.
Histopathological findings
Full histopathological examination was conducted and the results in the specific organs of which the relative weight had changed are summarized in Table 5 . In males, no abnormality of the thymus was noted in the 20 mg/kg group. In the spleen, grade 1 hemosiderin deposition with partial congestion was observed in all males in the 20 mg/kg group but no extramedullary hematopoiesis was recognized in any males including recovery animals. Hemosiderin deposition remained in 4 of 5 males at the end of the recovery period, and in one it was grade 2. Testicular examination of an infertile male in the 0.8 mg/kg group showed diffuse degeneration of the seminiferous tubules (bilateral) although the grade was low (data not shown). Another infertile male in the control group showed no abnormalities of the reproductive organs. On the other hand, some lesions were observed in the liver and kidneys. However, these were spontaneous findings since they showed a low incidence and/or were not dose dependent.
In females, atrophy of the thymus was noted in 4 of 12 animals in the 20 mg/kg group at the end of the administration period. In the spleen, mostly grade 1 hemosiderin deposition with partial congestion was observed in 11 of 12 females at 20 mg/kg while extramedullary hematopoiesis was observed in only 1 of 12 females at 20 mg/kg. Hemosiderin deposition remained in 2 of 5 females at the end of the recovery period. No abnormalities were observed in the ovaries and uterus of the two infertile females. Although a solitary cyst in the medulla of the kidney was observed in the 20 mg/kg group, it was considered to be a spontaneous lesion based on the low incidence. No abnormalities in other organs including the liver were observed.
Reproductive/developmental toxicity
There were no significant changes in the mean estrous cycle length and cyclicity in any group (data not shown). Reproductive/developmental parameters are described in Table 6 . The numbers of mated pairs, copulated pairs and pregnant females, including the related indexes, and gestation length were not affected by tBH administration. The only significant change was a decrease of approximately 20% in the number of corpora lutea in the 20 mg/kg group. Related to this reduction, the number of implantation sites in the same dose group was equally decreased although it was not statistically significant. Similarly, the numbers of several pups' parameters at the same dose were also low without a significant difference. Infertility was only observed in one female each in the control and 0.8 mg/kg groups. No other chemical-related changes were noted.
DISCUSSION
The present test demonstrated that a definitive repeated-dose toxicity of tBH was hemolytic anemia. No other adverse effects were observed in body weight, food intake, general appearance, functional observation, biochemical analysis or organ weights. The NOAEL of tBH was considered to be less than 0.8 mg/kg/day based on the decrease in anemic parameters such as hematocrit and hemoglobin concentration in females. This decision was reasonably supported by the Hazard Evaluation Committee for High Production Volume chemicals of the Japanese Ministry of Economy, Trade and Industry. On the other hand, regarding the histopathological examination, a hemolytic response such as congestion and hemosiderin deposition in the spleen was only observed in association with an increase in the reticulocyte ratio in both sexes at 20 mg/kg/day. These findings may indicate that clear hemolytic anemia occurred at 20 mg/kg/day, the high dose group in both sexes. Anemia, the most sensitive endpoint of tBH in a standard repeated-dose toxicity test in rats, is the same as that of hydrazine (MHLW, 2003a) . A higher sensitivity of females with hemolytic anemia due to tBH is the same, also in the 28-day repeated-dose studies of hydrazine monohydrate (MHLW, 2003a) and 4,4 '-oxybis (benzenesulfonylhydrazide) (MHLW, 2004a) , structurally similar substances, indicating that it is a common property of hydrazine derivatives. Studies of hydrazine monohydrate have also shown the formation of methemoglobin, and it also had a higher value in females than in males. Although there are no data on the disposition of tBH, it is estimated that tBH may cause the anemia via the production of methemoglobin in red blood cells as well as hydrazine monohydrate and a higher concentration of the active molecular form in red blood cells in females than in males as one possibility. On the other hand, anemia caused by hydrazine monohydrate or 4,4 '-oxybis (benzenesulfonylhydrazide) was recoverable, but the recovery property in case of tBH was very poor, with very little extramedullary hematopoiesis of the spleen. This poor extramedullary hematopoiesis may be the major reason why the anemia did not recover, suggesting that the target of tBH is not only red blood cells but the hematopoietic system. Since such poor recovery is rare, attention is required.
It is generally accepted that the hemolytic activity in Table 3 . Absolute organ weights in rats treated orally with tBH. Vol. 38 No. 2 red blood cells is a common toxicity of hydrazine derivatives. Phenylhydrazine is one of the most potent hemolytic agents and has been reported to induce anemia by several exposure routes in various animals since 1928 Giffin and Allen, 1928) . For example, Yeshoda (1942) demonstrated that phenylhydrazine induced a 50% reduction in red blood cells and a 40% reduction in hemoglobin concentration on day 4 by a single intraperitoneal injection to rats at a dose of 20 mg/kg. Exposure to pheylhydrazine may cause direct damage to red blood cells, potentially resulting in anemia and consequential secondary involvement of other tissues, such as the spleen and liver (Stern, 1989) , and phenylhydrazine-induced anemia has been used as a model for the test of hematinic effects in vitro (Biswas et al., 2005 ). An in vivo hemolytic effect was also reported for monomethylhydrazine in dogs (Jacobson et al., 1955) and monkeys (Haun et al., 1970) , 1,1-dimethylhydrazine in dogs (Rinehart et al., 1960) and acetylphenyhydrazine in rats (Tarumi et al. 1991) and dogs (Mayerson and Laurens, 1929) . As for therapeutics, there are some reports of anemia with hydralazine (Macleod, 1983) and procarbazine (Hadjiyanni et al. 1992) . However, the quality of most of the toxicity data is considered to be inappropriate as Hydrazine, phenylhydrazine and dimethylhydrazines are known structural analogs of tBH, and their toxicity information has been summarized (EHC, 1987; CICAD, 2000; US ATSDR, 1997) . The mechanism of the hemolytic anemia they cause was speculated as follows. Phenylhydrazine was first discovered to produce methemoglobin by reaction with oxyhemoglobin in a suspension of red blood cells (Heinz, 1890) . Hydrazine, phenylhydrazine and acetylphenylhydrazine react with oxyhemoglobin in red blood cells to produce cytotoxic species and induce hemolytic anemia in animals (Jain and Hochstein, 1979) . These reactions cause hemoglobin precipitates known as Heinz bodies (Jandl et al., 1960) . Free radical generation was also demonstrated based on the reaction of hydrazine or acetylphenylhydrazine with oxyhemoglobin and with human red blood cells using spin trapping material (Thornalley, 1984) . On the other hand, hydrazines stimulated proteolysis in red blood cells, which was demonstrated as an increased rate of tyrosine release, suggesting that proteolytic enzymes exert a protective effect against cellular damage (Runge-Morris et al., 1988) . Although there is no mechanistic information on tBH-induced anemia, it is expected that tBH may react with red blood cells by a similar mechanism as other hydrazine derivatives. It has increased the possibility that the QSAR approach to predict the toxicity of the hydrazine derivatives should be applied since tBH showed clear anemia results in the present study as has been expected since before. However, the test results of some major substances such as 1,1-dimethylhydrazine and phenylhydrazine by the standard test methods are required to predict the anemia potency more appropriately by the QSAR approach.
As mentioned before, appropriate repeated-dose toxicity data using rats conducted by standard methods are available for a limited number of hydrazine derivatives including tBH. Their NOAELs simply based on a significant reduction in anemic parameters were 3 mg/kg/day for hydrazine, 30 mg/kg/day for 4,4'-oxybis(benzenesu lfonylhydrazide) and < 0.8 mg/kg/day for tBH. By this comparison, tBH seems to demonstrate the strongest anemic intensity among them, followed by hydrazine, which has 3-fold less potency, and the other derivatives, which have even less potency. However, it is considered that this NOAEL comparison approach would not express the real overall profile if we look at the full measured data set. Therefore, a more appropriate comparison of anemic intensity was applied using the actual measured data of red blood cell count, hemoglobin concentration and hematocrit. For this purpose, a benchmark dose (BMD) approach was used. The BMD lower bound at a relative deviation of 10% at the 95% confidence level (BMDL 10 ) was calculated by the US EPA provided Benchmark Dose Software (Version 2.1.2). The calculation was performed by the Continuous Model Type with Model Name of Power. The average of three parameters such as red blood cell count, hemoglobin concentration and hematocrit for males and females, was 21 and 13 mg/kg/day for hydrazine, 108 and 101 mg/kg/day for 4,4'-oxybis(benze nesulfonylhydrazide), and 18 and 11 mg/kg/day for tBH, respectively. Based on the results of this approach, the anemic intensity of tBH is considered to be mostly equal to that of hydrazine, and approximately 10-fold stronger than that of 4,4'-oxybis(benzenesulfonylhydrazide). In the same way, it is considered that this BMD approach concludes in an appropriate outcome of the anemic intensity of the three chemicals.
The only other significant changes of repeated-dose toxicity were an increase in the relative weight of the liver and kidneys in 20 mg/kg/day females. However, these are not considered to be an adverse effect, because no histopathological or related biochemical abnormalities were noted.
As for the reproductive/developmental toxicity of tBH, a significant reduction in the number of corpora lutea such as 16.0 for the control to 13.1 at 20 mg/kg/day, should be considered to be a chemical-related effect, because the historical background of the average number of corpora lutea ranged from 14.5-16.9 based on the last 12 studies at our facility. The number of implantation sites was slightly, but not significantly, reduced, probably related to the decreased number of corpora lutea. Although the numbers of pups born and live pups born were slightly low, it may also be due to the decreased number of corpora lutea. This reproductive toxicity of tBH is not considered to be so serious, compared with a clear reproductive toxicity of hydrazine such as no live pups, probably due to the lethality of embryos at an oral dose of 18 mg/kg/ day in the preliminary reproductive test (MHLW, 2003b) . This difference in the severity and kind of reproductive toxicity may suggest that hemolytic anemia is not simply a direct cause of such serious reproductive toxicity of hydrazine, because the anemic intensity of hydrazine is almost the same as that of tBH.
One female in the control or 0.8 mg/kg/day groups was infertile. Although the females in both groups and the mating partner male from the control showed no abnormalities of the genitals or subgenitals, a mating partner male at 0.8 mg/kg/day had bilateral degeneration of the seminiferous tubules. However, the reason of the infertility was uncertain even in case it was the 0.8 mg/kg/day group, because the testicular change was only slight and not dose-related.
In summary, values of the anemic parameters were decreased in males in the 20 mg/kg/day group and females in all the dose groups with congestion and hemosiderin deposition in the spleen in both sexes in the 20 mg/kg/day group. As for reproduction, significant reduction was only observed in the number of corpora lutea at 20 mg/kg/day. Based on these findings, it was concluded that 0.8 mg/kg/day was the LOAEL based on decreased values of the anemic parameters of repeateddose toxicity and the NOAEL was 4 mg/kg/day due to the low number of corpora lutea of reproductive/developmental toxicity.
